Search Results

China's largest single-building oncology nuclear medicine center to be completed and put into operation in Luzhou, Sichuan

On September 2, the "Myriad Weather in Sichuan · Starting Strong for the '15th Five-Year Plan'" Luzhou special press conference was held in Chengdu. The conference disclosed that China's largest single-building oncology nuclear medicine center is about to be completed and put into operation in Luzhou, Sichuan. Construction site of the Oncology Nuclear Medicine Center of the Affiliated Hospital of Southwest Medical University. The center is a key project of Sichuan Province's regional medical centers. The project has a total investment of 310 million yuan, covers an area of approximately 15,000 square meters, and plans more than 160 beds. It will integrate functions including nuclear medicine molecular imaging, nuclear drug R&D and preparation, radionuclide therapy, tumor radiotherapy, and specialized oncology diagnosis and treatment, and will be built into...

2026-09-03

Beijing Jiluntai's ¹⁷⁷Lu-JLT003 Injection Receives IND Approval for Treatment of Integrin αvβ3-Positive Malignant Tumors

Beijing Jiluntai Pharmaceutical Co., Ltd. has recently achieved progress in radiopharmaceutical R&D. Its self-developed Class 1 innovative therapeutic radiopharmaceutical ¹⁷⁷Lu-JLT003 Injection (generic name: ¹⁷⁷Lu-AB-3PRGD2) has obtained the Clinical Trial Approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), intended for the treatment of integrin αvβ3-positive malignant tumors. ¹⁷⁷Lu-AB-3PRGD2 is a therapeutic radiopharmaceutical targeting integrin αvβ3. Integrin αvβ3 is highly expressed on various solid tumor cells and tumor neovascular endothelial cells, while showing low expression in normal tissues, a characteristic that...

2026-09-01

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

Russian Thorium-Based Radiopharmaceuticals Expected Within 1-2 Years

On August 27, Igor Korobko, Professor of the Russian Academy of Sciences and Director of the Department of Medical and Scientific Development in Healthcare of the Russian Ministry of Health, stated at the Technoprom Forum held in Novosibirsk that thorium-based drugs for precision radionuclide therapy of tumors are expected to become available in Russia within the next 1 to 2 years. Korobko noted that tumor treatment still requires support from more available isotopes. For example, when patients develop resistance to actinium-related therapies, clinical practice necessitates the use of different isotopes for treatment. He stated that Russia is advancing the development of related therapies domestically and expects to have thorium-based drugs within the next year or two. Currently, actinium-225 is considered one of the more promising radionuclides...

2026-08-28

Angolan Public Health and Medical Training Delegation Visits the Affiliated Hospital of Southwest Medical University, Focusing on Nuclear Medicine Diagnosis and Treatment Technologies

Recently, the "Angola Public Health and Medical Training Program," organized by the International Exchange Center of the Sichuan Provincial Health Commission, was held at the Affiliated Hospital of Southwest Medical University. An 18-member delegation comprising Angolan health administrators and medical personnel visited the hospital for exchange, with a focus on learning about the development and clinical application of nuclear medicine, urology, and other related disciplines. Jiang Yong, member of the Standing Committee of the Party Committee, Vice President of Southwest Medical University, and President of the Affiliated Hospital, welcomed the Angolan delegation and introduced the hospital's basic information. He stated that under the guidance of the Sichuan Provincial Health Commission, the hospital will leverage its disciplinary advantages as a university-affiliated hospital and a Sichuan Provincial Medical Center to carry out practical cooperation with Angola in talent cultivation, technical exchange, and hospital management.

2026-08-25

Vivos Ships First Batches from U.S. IsoPet Production Facility, Receives AERB Approval to Build International Manufacturing Center in India

KENNEWICK, Wash. — Vivos Inc. recently announced two operational milestones: its in-house production facility in Richland, Washington, has begun delivering IsoPet® products to certified veterinary clinics in the United States; simultaneously, the company has received authorization from India's Atomic Energy Regulatory Board (AERB) to establish an international manufacturing center in India. This means Vivos will have a two-site production footprint spanning the U.S. and India. According to the company, the U.S. production facility, housed at the Applied Process Engineering Laboratory (APEL), will manufacture IsoPet® veterinary oncology products and RadioGel® human oncology products, and will serve as the center for subsequent process improvements and regulatory...

2026-08-19

South Korea to Resume Actinium-225 Production Next Year to Ease Shortage of Raw Materials for Anti-Cancer Radiopharmaceuticals

South Korea's domestic production project for actinium-225 (Ac-225), a radioisotope used in next-generation cancer treatment, is expected to resume next year after being stalled for more than a year. Funding was secured in the first half of this year, and the Korea Institute of Radiological & Medical Sciences (KIRAMS) plans to complete facility construction and trial production before launching full-scale production in the second half of next year, aiming to alleviate the raw material shortage facing domestic clinical research and radiopharmaceutical development. KIRAMS is affiliated with the Ministry of Science and ICT. The institute received approval from the Nuclear Safety and Security Commission in May last year to produce Ac-225 using a cyclotron. The project first entered the review process in 2018 and took seven years to gain approval, with initial production originally planned by the end of last year. However, work on upgrading production facilities and procuring equipment was suspended after approximately 2 billion KRW in budget was not approved during parliamentary review.

2026-08-10

Russian State Expert Review Authority Approves Design Changes for Ufa Radionuclide Therapy Center

Russia approves design changes for the Ufa Radionuclide Therapy Center, which will employ the latest technologies and equipment. The new center, located in the Republic of Bashkortostan, is expected to become a significant force in the local fight against cancer. With a floor area exceeding 6,000 square meters, the facility is a G-shaped three-story building with a basement. Its internal framework uses monolithic reinforced concrete to ensure stability and safety. The project's design strictly adheres to medical technology standards, aiming to create a modern and innovative treatment institution. At the core of the center is the radionuclide therapy department, which includes 24-hour inpatient wards, featuring a radionuclide supply area, a 20-bed "active" ward, and common areas. Additionally, it includes service and administrative zones to support the center's daily operations...

2026-08-01